Jane might be able to speak to why it's important to have the bill have the higher powers in terms of being nimble in circumstances where you really do have to act very fast in the interest of public safety or public health.
In terms of the pharmaceuticals, they were certainly involved in consultations. In Quebec, for instance, the GSK and others were at some of these sessions. It is true they have not voiced any concerns with this current bill. I think all of them already import pathogens, for example, already under current regulation, and they have not voiced specific concerns to us. But it would be interesting, for sure, to hear from some of these areas.